Wedbush Launches Coverage on Cross Country Healthcare, Cross Country Stock Quotes Signal 29% Upside

Wedbush Securities initiated research coverage of Cross Country Healthcare (CCRN) on February 3, 2026, assigning a Neutral rating to the healthcare staffing company. The analyst team has established a balanced stance on the stock, suggesting investors carefully weigh both opportunities and risks. Current cross country stock quotes from major analysts show meaningful appreciation potential, with the consensus price target reaching $11.68 per share—a 29.79% increase from the latest closing price of $9.00.

The analyst price forecasts for cross country stock quotes display a wide range, spanning from $8.74 on the conservative end to $19.54 on the optimistic side, reflecting divergent views on the company’s trajectory. Wedbush’s Neutral rating sits comfortably within this spectrum, acknowledging both the bull and bear cases. Beyond the stock price appreciation potential, Cross Country Healthcare is projected to generate annual revenue of $1,662 million, representing a substantial 47.41% year-over-year increase. The projected non-GAAP EPS stands at $2.49, underscoring improving operational profitability.

What Do Analyst Quotes and Valuations Tell Us?

The range of cross country stock quotes among analysts reflects cautious optimism about the company’s near-term performance. While the 29.79% upside from current levels may appeal to growth-oriented investors, Wedbush’s neutral stance suggests the risk-reward at current prices is balanced rather than skewed decisively in either direction. This measured approach aligns with the company’s mixed fundamentals—strong revenue growth paired with moderate earnings improvements.

How Are Major Funds Positioned in Cross Country Healthcare?

Institutional investor positioning reveals a nuanced market view. As of the latest data, 311 funds and institutions report positions in CCRN, though this represents a decline of 52 owners (14.33%) from the prior quarter. The average portfolio weight dedicated to CCRN across all funds stands at 0.07%, up 13.20% on a relative basis. However, total institutional share count fell 1.84% to 34.452 million shares, suggesting selective profit-taking or rebalancing among fund managers.

The options market sentiment appears constructively tilted, with a put/call ratio of 0.47. This below-1.0 reading indicates more bullish positioning in call options relative to puts, suggesting traders anticipate upside moves in the near term—a view that contrasts somewhat with Wedbush’s measured Neutral rating.

Which Institutional Investors Are Making Moves?

Major shareholders reveal interesting dynamics in cross country stock positioning:

Magnetar Financial maintains its largest stake at 2.474 million shares (7.55% ownership) with no changes in the latest quarter, suggesting confidence in its current position.

Alliancebernstein reduced its holdings from 2.438 million to 1.931 million shares (5.89% ownership), cutting exposure by 26.29% and lowering its overall portfolio allocation by 31.33%. This significant retreat may signal caution about near-term prospects despite the longer-term growth narrative.

Oddo Bhf Asset Management holds 1.575 million shares (4.81% ownership) unchanged from the prior quarter, maintaining steady exposure.

Vanguard’s Total Stock Market Index Fund holds 1.011 million shares (3.09% ownership) through its passive tracking approach, with no active changes.

Goldman Sachs increased slightly from 947K to 987K shares (3.01% ownership, +4.05% increase), yet paradoxically cut its portfolio allocation by 76.05%—likely reflecting broader fund rebalancing rather than a specific stance on the company.

The Bottom Line on Cross Country Healthcare

Wedbush’s initiation with a Neutral rating, combined with mixed signals from institutional investors, paints a cautious picture for cross country stock quotes in the near term. While the 29% analyst upside and strong projected revenue growth provide supporting arguments for bulls, the retreat by major funds like Alliancebernstein and the balanced options market sentiment suggest investors should await clearer catalysts before increasing exposure. The valuation, while not expensive, doesn’t appear to offer a compelling margin of safety at current levels—a conclusion that aligns perfectly with Wedbush’s middle-ground positioning.

Data sourced from Fintel and public SEC filings as of February 3, 2026.